Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself at the intersection of precision oncology, artificial intelligence, and automation by advancing its integrated technology portfolio. The company's Deciparticle nanomedicine platform, developed through its relationship with Sapu Nano, addresses challenges with hydrophobic drugs, including poor solubility and limited bioavailability. This platform is central to Oncotelic's strategy to improve how therapies are developed, manufactured, and delivered for difficult-to-treat diseases.
The company's PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. This integration allows Oncotelic to leverage AI, nanomedicine, and automation to accelerate the development of therapies for cancer and rare diseases. The PDAOAI system helps analyze vast amounts of data to identify potential drug candidates and optimize treatment protocols.
Oncotelic's international development initiatives are expanding, supporting future therapeutic and commercial opportunities. The company is focusing on building an integrated technology portfolio that combines cutting-edge approaches to overcome longstanding challenges in drug development. By using nanomedicine to improve drug delivery, AI to accelerate discovery, and robotics to automate manufacturing, Oncotelic aims to bring new treatments to patients more efficiently.
For more information on Oncotelic's latest news and updates, visit the company's newsroom at ibn.fm/OTLC. Additional details on the PDAOAI ecosystem and its applications can be found at ibn.fm/lU39h.
InvestorWire, a specialized communications platform, syndicated this press release. The platform focuses on advanced wire-grade press release syndication for private and public companies. It is part of the Dynamic Brand Portfolio @IBN, which provides access to a vast network of wire solutions, article syndication to 5,000+ outlets, enhanced press release distribution, and social media distribution to millions of followers. InvestorWire aims to help companies reach investors, influencers, consumers, journalists, and the general public.
For more information about InvestorWire, visit https://www.InvestorWire.com. Full terms of use and disclaimers are available on the InvestorWire website.
